Strong germinal force field of prostate cancer treatment
Zytiga is Johnson & Johnson in 2009 to $ 1 billion acquisition of Cougar Biotechnology, Inc. obtained after in 2011, only to be approved for patients with prostate cancer that has spread. While Zytiga only after two years in the market to become a blockbuster, but in 2016 the drug may be cheap in the U.S. market is facing generic competition, while ARN-509 in the U.S. market the exclusive sales rights will extend to 2028.
Leerink Swann analyst Danielle Antalya non (Danielle Antalffy) in a research report, said: "We expect that Johnson & Johnson will accelerate the ARN-509 development schedule, and expand the drug's clinical trial program for the depth , resulting in the loss of U.S. patent protection Zytiga prior to ARN-509 to the market. "
On the use of inhibitors of testosterone without benefit of those patients, Zytiga and ARN-509 will become their drug candidates. Testosterone is to stimulate the development of prostate cancer, androgen. However, Zytiga ARN-509, and these two different mode of action of drugs. Antalya non-representation, ARN-509 has the potential to become one of the most effective in these patients treatment.
Strong germinal force field of prostate cancer treatment
ReplyDeleteZytiga is Johnson & Johnson in 2009 to $ 1 billion acquisition of Cougar Biotechnology, Inc. obtained after in 2011, only to be approved for patients with prostate cancer that has spread. While Zytiga only after two years in the market to become a blockbuster, but in 2016 the drug may be cheap in the U.S. market is facing generic competition, while ARN-509 in the U.S. market the exclusive sales rights will extend to 2028.
Leerink Swann analyst Danielle Antalya non (Danielle Antalffy) in a research report, said: "We expect that Johnson & Johnson will accelerate the ARN-509 development schedule, and expand the drug's clinical trial program for the depth , resulting in the loss of U.S. patent protection Zytiga prior to ARN-509 to the market. "
On the use of inhibitors of testosterone without benefit of those patients, Zytiga and ARN-509 will become their drug candidates. Testosterone is to stimulate the development of prostate cancer, androgen. However, Zytiga ARN-509, and these two different mode of action of drugs. Antalya non-representation, ARN-509 has the potential to become one of the most effective in these patients treatment.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
ENMD-2076 TARTARIC ACID
ENMD-2076
SNS-314
CCT129202
Hesperadin
PF-03814735
AT9283
GSK-1070916
MK-5108
Aurora A inhibitor I